Accolade
- 🦄Became a unicorn2020
- 📈Peak valuation$3.5 Billion ’21
- 💔Became a Unitard~2022
- 💸Last valuation~$630M
How it happened
Accolade paired human advocates with technology to help large employers' staff find care, understand benefits and get expert medical opinions. It went public in 2020 and rode the pandemic-era digital-health wave to a roughly $3.5B market value in early 2021. As growth slowed and the sector deflated its shares collapsed, and in early 2025 rival Transcarent took Accolade private for $621M — about $7.03 a share — delisting it from Nasdaq. Glassdoor reviews from the slide describe year-after-year layoff rounds, some cutting hundreds of roles at a time, plus frequent reorganizations, senior-leadership churn, repeated return-to-office reversals, and frontline jobs increasingly shifted to lower-cost sites in Prague and other countries.
Employee accounts paraphrase anonymous, unverified reviews posted publicly on Glassdoor ↗. See our methodology.
Source: STAT News / CNBC / Healthcare Dive (health-benefits navigation and advocacy platform backed by Andreessen Horowitz, Carrick Capital and McKesson Ventures; IPO'd in 2020 and peaked near a $3.5B market cap in early 2021, then slid as growth slowed; Glen Tullman's Transcarent — funded by General Catalyst and 62 Ventures — agreed in January 2025 to take it private for $621M, or $7.03 a share, completing the deal in April 2025)
